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Abstract 
Mutation in the triggering receptor expressed on myeloid cells (TREM) 2 gene has been identified as a 
risk factor for several neurodegenerative diseases including Alzheimer’s disease (AD).  Experimental 
studies using animal models of AD have highlighted a number of functions associated with TREM2 
and its expression by microglial cells.  It has therefore been assumed that this is also the case in 
humans.  However, there is very limited information concerning the cellular expression of TREM2 in 
the human brain.  As part of investigations of microglia using post-mortem resources provided by the 
Medical Research Council Cognitive Function and Ageing Studies (MRC-CFAS), we immunostained 
the cerebral cortex of 299 participants for TREM2 using the Sigma antibody HPA010917 and 
compared with the macrophage/microglial markers Iba1 and CD68.  As expected, Iba1 and CD68 
labelled microglia and perivascular macrophages.  However, in most cases (284/299), the TREM2 
antibody labelled monocytes within vascular lumens, but not microglia or perivascular macrophages.  
In contrast, in 5 out of 6 cases with acute infarcts, TREM2 immunoreaction identified cells within the 
brain parenchyma interpreted as recruited monocytes.  Six cases with old infarcts contained 
phagocytic foamy macrophages which were CD68-positive but TREM2 negative.  Our observations, 
using the HPA010917 anti-TREM2 antibody, suggest that TREM2 is not expressed by microglia but 
instead seems to be a marker of recruited monocytes in the human brain.  This finding has 
implications with regards to the role of TREM2 as a risk factor, emphasizing the importance of 
systemic immune responses in the development and progression of Alzheimer’s disease. 
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Introduction 
Heterozygous mutation in triggering receptor expressed on myeloid cells (TREM) 2 gene has 
been identified as a risk factor for several neurodegenerative diseases including Alzheimer’s disease 
(AD) (10, 20), amyotrophic lateral sclerosis (5), and Parkinson’s disease (24).  TREM2 is a 
transmembrane receptor of the immunoglobulin family, which associates with the adapter protein 
DAP12 for signaling.  The TREM2/DAP12 pathway is involved in the activation of human dendritic 
cells derived in vitro from monocytes (2) and thus TREM2 is thought to be involved in innate 
immunity.  The importance of TREM2 in brain function has been illustrated by the autosomal 
recessive disorder Nasu-Hakola disease (NHD) due to homozygous loss-of-function mutations in the 
TREM2 gene (11, 31), in which affected people develop a presenile frontotemporal dementia with 
sclerosing leukoencephalopathy and polycystic lipomembranous osteodysplasia,  Neuropathological 
features of NHD include demyelination and massive gliosis (41).  It was then hypothesized that 
microglia, as the resident immune cells of the brain, might express TREM2.  This was confirmed in 
adult murine microglia with regional variations of TREM2 expression in the brain (12, 35), and it was 
suggested that TREM2 was implicated in the phagocytosis of apoptotic neurons without triggering an 
inflammatory response (17, 37), an essential function of healthy microglia. 
TREM2 mutation was identified as a significant risk factor for AD with an effect size comparable 
with that of the ε4 allele of apolipoprotein E (APOE) gene (10, 20), although it is considerably less 
common.  The role of TREM2 in the brain has been mainly been investigated in different mouse 
models of AD.  In APP23 transgenic mice, which carry the human Swedish mutation APP 
KM670/671NL, TREM2 expression was observed to be associated with the progression of amyloid 
deposition with microglia clustering around amyloid plaques (8).  While in the APP/PS1 transgenic 
mice (Swedish and PSEN1 L166P mutations) lacking one copy of the TREM2 gene, a reduced 
number of microglia associated with plaques was observed without alteration of the amyloid load 
(40).  Recently it was shown that in the 5XFAD transgenic mice (5 point mutations in the human APP 
and PSEN1 genes), the function of microglial TREM2 is to sense lipids promoting microglial survival 
and clustering around Aβ plaques (42), supporting a protein microarray study that identified the 
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apolipoproteins ApoE and Clusterin/ApoJ as ligands for human TREM2 (43).  Despite the 
discrepancies in these studies regarding the role of TREM2 in amyloid deposition, possibly due to the 
differences in the transgenic mouse models used, the findings are consistent with a direct or indirect 
role for TREM2 in myeloid cell migration, proliferation, survival and phagocytosis. 
In contrast to animal studies, investigation to localise TREM2 expression in the human brain has 
been sparse.  In a post-mortem study involving 11 controls, 11 possible AD and 11 AD cases, the 
highest level of TREM2 by Western blot was found in the AD cases followed by the possible AD 
cases compared to controls, using the R&D antibody AF1828.  By double staining with this antibody 
and the microglial marker HLA-DR, they observed TREM2 expressed in some microglia and neurons 
(27).  A survey of 7 commercial TREM2 antibodies on formalin-fixed paraffin-embedded post-
mortem brain tissue found only 3 antibodies to bind with human recombinant TREM2 protein on 
Western blot, performed to test their specificity.  The 2 best TREM2 antibodies were the Sigma 
HPA010917 and the R&D AF1828 antibodies (33), also validated using the same methodology by the 
companies Sigma (www.proteinatlas.org) and R&D.  Therefore, to investigate the localization of 
TREM2 in the human brain, we have used the cohort of the Medical Research Council Cognitive 
Function and Ageing Study (MRC CFAS) in which we have also studied multiple other microglial 
proteins (30).  We screened 299 brains unselected from the whole spectrum of cognitive function 
found in population samples, including any dementia type and treatment but characterized in terms of 
clinical and neuropathological data (3, 34) with the HPA010917 and AF1828 anti-TREM2 antibodies. 
 
Materials and methods 
The CFAS cohort 
The Medical Research Council Cognitive Function and Ageing Study (MRC CFAS) has been 
recruiting individuals living in the community aged 65 years and over since 1990 (3).  The main aims 
were to estimate the prevalence and incidence of cognitive decline and dementia; to determine the rate 
of progression of cognitive decline and survival, and to identify risk factors for cognitive decline and 
dementia.  Participants were invited to consent to brain donation after death.  The ascertainment of 
dementia status at death has been described in detail (34) and was based on review of information 
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available from death certificates, last interview assessment and the informants' information about 
participants’ function and cognition (Mini Mental State Examination – MMSE- score) during the last 
years of life.  Brains sections from 299 participants were used in this study with the demographic and 
cognitive profile of the cohort described in Table 1.  All analyses were conducted blind to in vivo 
state. 
 
Immunohistochemistry 
Optimisation of the staining for the polyclonal rabbit anti-TREM2 antibody HPA010917 (Sigma, 
Gillingham, UK) and the polyclonal goat anti-TREM2 AF1828 (R&D, Abingdon, UK), was 
performed using different antigen retrieval pretreatments on splenic tissue, a myeloid organ used as a 
positive control.  These included: (i) no pretreatment, (ii) heat retrieval pretreatment with either (a) 
citrate buffer pH6, or (b) EDTA buffer pH8.  The best immunodetection was obtained with the 
HPA010917 anti-TREM2 antibody at a concentration of 1:100 after EDTA pH8 microwave 
pretreatment (Fig 1).   
Four µm sections of formalin-fixed paraffin-embedded tissue from the middle frontal gyrus were 
screened for TREM2 protein immunoreactivity using the HPA010917 anti-TREM2 antibody under 
the same conditions.    
Biotinylated secondary antibody from Dako (Glostrup, Denmark) was visualized using the 
avidin-biotin-peroxidase complex method (Vectastain Elite ABC from Vector Laboratories 
(Peterborough, UK)) with 3,3’ diaminobenzidine (DAB, Vector Laboratories (Peterborough, UK)) as 
chromogen and 0.05% hydrogen peroxide as substrate.  All sections were counterstained with 
haematoxylin then dehydrated before mounting in DePeX (VWR International, Lutterworth, UK).  
For each run, sections incubated in the absence of the primary antibody were included as negative 
controls, and a section of spleen was included as a positive control to ensure staining consistency 
across the different runs (Figure 1A). 
All 299 cases were assessed for parenchymal TREM2 immunostaining blinded to the identity of 
the cases by 2 independent assessors (MF and DB).  Morphological pathological features were 
assessed on sections stained with haematoxylin and eosin (H&E).  The identification and assessment 
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of the infarcts was performed by an experienced neuropathologist (JARN) on the H&E stained slides 
according to the current classification (Table 2) (7, 16, 21).  TREM2-positive cells were scored within 
the identified infarcts using x20 objective magnification and reported as: - = 0; + = 1-20; ++ = 21-50; 
+++ = >51 per field; and for CD68-positive cells as: - = 0; + =1-20; ++ = 21-100; +++ = >101 per 
field. 
Sections previously stained for the microglial phagocytic markers Iba1 (rabbit polyclonal, Wako, 
Japan) and CD68 (clone PG-M1, Dako Glostrup, Denmark) (30) were reviewed. 
 
Results 
TREM2 expression in the spleen 
The spleen contains numerous monocytes/macrophages and so is a suitable choice for a TREM2 
positive control for immunohistochemistry.  Only the Sigma antibody HPA010917 was able to detect 
the monocytes/macrophages (Figure 1A).  No staining was obtained on the same spleen with the R&D 
AF1828 antibody despite the use of different pretreatments for antigen retrieval (Figure 1B).  
Therefore, the CFAS brain sections were screened for TREM2 expression using the HPA010917 
antibody. 
 
Microglia and perivascular macrophages in the human brain are TREM2 negative  
In the cerebral cortex, Iba1 immunohistochemistry demonstrated microglia as expected with 
typical morphology, having numerous short processes (ramified microglia), and perivascular 
macrophages (Figure 2A).  In contrast, the microglia and perivascular macrophages were TREM2 
negative (Figure 2B), with TREM2 immunoreactivity detected only in cells in blood vessel lumens, 
having round nuclei and scanty cytoplasm morphologically consistent with circulating monocytes 
(Figure 2B) and acting, in effect, as an internal positive control.  The TREM2-positive intravascular 
monocytes were observed in all 299 cases.  In addition 15 of the 299 cases, in which small infarcts 
were detected within the sections, presented another pattern of staining as described below. 
 
Parenchymal TREM2 positive cells in acute infarction 
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Interestingly, in contrast to the situation in relatively normal brain tissue, extravascular TREM2-
positive cells were identified in regions of acute infarction included in the tissue sections.  Iba1 
immunohistochemistry identified microglia with mainly ramified morphology (Figure 2C), which 
were TREM2 negative (Figure 2D), and this was observed within the 299 cases.  However, TREM2 
immunolabelling was detected in extravascular parenchymal cells within the acutely infarcted zone.  
These TREM2 positive parenchymal cells had similar morphology to the intravascular monocytes and 
are likely to represent circulating monocytes that have been recruited from the circulation into the 
brain parenchyma in response to the infarct (Figure 2C-D).   
Sixteen infarcts were identified in H&E-stained sections on morphological grounds in 15 of the 
299 cases studied in total (Table 3).  The histological stage of evolution of the infarcts was assessed 
which, in turn, could give approximate ages to the lesions (Table 2) (7, 16, 21).  No parenchymal 
TREM2 immunoreactivity was observed in the 2 cases with very acute infarcts (<24 hours) preceding 
a cellular reaction (Figure 3A-C), or in the 6 old infarct cases (> several weeks old) despite abundance 
of foamy macrophages and CD68 immunoreactivity at that stage (Figure 3G-I, Table 3).  In contrast, 
TREM2 immunoreactivity in the brain parenchyma was identified in 5 out of 6 acute infarcts (1-3 
days) (Figure 3D-F, Table 3).  The TREM2-positive cells in the acute infarcts had round nuclei and 
scanty cytoplasm, and were confined to the infarcted tissue, thus likely representing monocytes 
migrated from the circulation into the infarct.  One out of 2 cases with a subacute infarct (~1 week 
old, overlap stage between acute and old infarct) had both TREM2 and CD68 immunolabelled 
macrophages (Table 3). 
 
Discussion 
Our findings of a positive TREM2 signal in the splenic macrophages with the HPA010917 
antibody are consistent with the antibody characterisation study which identified that this antibody is 
specific for TREM2 both in vitro and in vivo (33) and expressed on myeloid cells.  Our unexpected 
findings in the human brain revealed firstly that, although abundant microglia were identified by 
immunoreactivity for Iba1, the microglia did not express TREM2 in the 299 cases of the CFAS 
cohort.  This was despite TREM2 positivity of monocytes within the lumens of blood vessels in the 
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sections of brain tissue, representing monocytes circulating in the blood.  Secondly, TREM2-positive 
cells were present within the brain parenchyma in acute infarcts (1-3 days approximately).  These 
TREM2-positive cells had the morphology of monocytes and macrophages, rather than process-
bearing microglia, and seem likely to be monocytes recruited from the bloodstream in response to the 
infarct; subsequently evolving into macrophages as they begin to phagocytose the necrotic tissue.  As 
expected, these acute infarcts prior to the onset of phagocytosis, lacked staining with the lysosomal 
marker CD68.  In contrast, older infarcts in which phagocytosis is taking place contained CD68-
positive macrophages, consistent with previous studies in humans and laboratory animals (1, 9, 28), 
but these macrophages lacked TREM2 immunoreactivity.  Interestingly, one of the two subacute 
infarcts cases had immunoreactivity of cells for both TREM2 and CD68.  These findings imply that 
following infarction and the breakdown of the blood-brain barrier, TREM2-positive CD68-negative 
monocytes invade the brain parenchyma at the site of the injury (consistent with the role of TREM2 
expression in chemotaxis (29)), differentiate into TREM2-positive CD68-positive macrophages that 
became, over a period of about a week, phagocytic CD68-positive TREM2-negative macrophages.  
The subacute infarct, approximately one week in age (7, 16, 21), support this phenotypic change by 
having both TREM2 and CD68 immunoreactivity in morphologically macrophage-like cells present 
within the damaged parenchyma.  In the cases with infarcts, in the surrounding uninvolved brain 
parenchyma microglia were immunoreactive for Iba1, showed variable degrees of CD68 expression, 
but were consistently unlabelled for TREM2, (30).   
Overall, it appears that the TREM2 antibody employed in this study (HPA010917) labels 
specifically monocytes circulating in the bloodstream and monocytes recruited from the blood into the 
brain parenchyma in response to tissue injury, but not microglia resident within the brain.  We are 
acknowledging that the level of TREM2 expression in microglia could be below the level of detection 
by our methods.  It is theoretically possible that lack of microglial immunoreactivity with this 
antibody could be due to cleavage of the TREM2 protein proximal to the binding site of the antibody, 
but such cleavage would have to be selective for microglia and not monocytes or macrophages.  The 
antibody has been raised against a recombinant 35 amino acid sequence (amino acids 196-230) of 
TREM2 corresponding to the cytoplasmic sequence.  The identified cleavage site of TREM2 C-
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terminal to histidine 157 sheds an ectodomain but appears to leave the HPA010917 antibody binding 
site within the cell cytoplasm (23, 39), consistent with the cytoplasmic signal detected on the tissue.   
Our observations are consistent with: (i) the original study of the characterization of TREM2 in 
human immature monocyte-derived dendritic cells (2), (ii) the findings in one control and one AD 
case using the same antibody in the previous study assessing the sensitivity specificity of TREM2 
antibodies by Western blot followed for the HPA010917 antibody by immunohistochemistry after 
preabsorption with the recombinant protein to confirm the specificity (33), (iii) with the detection of 
TREM2 expression in in monocyte-derived macrophages but not microglia in APP/PS1 mice (19), 
and (iv) the absence of association between TREM2 and Iba1 protein levels detected by Western blots 
in human frontal cortex (32).  Our findings are also in accord with the proposed role of TREM2 as 
regulator of phagocytosis, as the brain parenchymal cells labelled in this study are indeed performing 
a phagocytic function in clearing necrotic tissue debris in infarcts. 
We did not observe any TREM2 staining around plaques in the CFAS cases with AD pathology, 
therefore providing no evidence that in humans peri-plaque microglia are derived from circulating 
monocytes.  Our observation appears different from a previous study on 11 post-mortem cases that 
describes TREM2 immunoreactivity on microglia associated with plaques using the R&D AF1828 
antibody.  In this study, the authors checked the specificity of the antibody using Western blot 
analysis but they did not carry out TREM2 immunodetection on a positive myeloid tissue (27).  A 
previous study demonstrated that whereas this antibody was able to recognise human recombinant 
TREM2 on Western blot, it was not able to label monocytes/macrophages, dendritic cells or 
osteoclasts on human tissue (33).  Of note, the authors did not perform single immunodetection of 
TREM2, but instead presented high magnification pictures of double staining with HLA-DR using 
light microscope.  The quality of the staining required arrows to indicate the positive cells questioning 
its reliability. 
Our findings counter the observations in animal models, such as the ones in the APP23 and the 
APPswe/PS1dE9 models using a Santa Cruz TREM2 antibody (8 {Jiang, 2014 #4121) or in the 
5XFAD using a R&D TREM2 antibody (44).  These studies observed (i) upregulation of TREM2 
expression during disease progression, (ii) TREM2-positive microglia and (iii) TREM2-positive 
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microglia around plaques.  Therefore, our own observations appear to challenge the fidelity of the 
animal models relating to this aspect of the complexity of human AD pathophysiology.  Importantly, 
the time-frame also differs: in the experimental models, the response was typically studied after a 
matter of few months; whereas the brains of the patients with dementia are being studied several years 
following the onset of the disease.  However, one of the strengths of the CFAS cohort is that it is the 
result of an unbiased representation of the elderly population and thus includes people at all stages of 
AD including early stages of plaque formation.  Some human studies have identified the presence of 
TREM2 in human brain tissue using biochemical methods only (e.g. Western blot, mRNA).  They do 
not contradict our findings as human brain tissue homogenates will include circulating monocytes 
within the lumens of blood vessels and so these methods will not distinguish between these cells and 
microglia. 
Our study in a large cohort of human post-mortem cases does not contradict the evidence for the 
role of TREM2 and the immune system as risk factors for AD despite the absence of TREM2-positive 
microglia.  The genetic data suggest that TREM2 gene variation, although rare, can alter risk as 
substantially as APOE genotype (10, 20).  Instead, it draws attention to an important role for 
peripheral myeloid cells, consistent with a role for systemic inflammation, in the development and 
progression of AD (13).  Of note, a recent study observed increased peripheral blood TREM2 mRNA 
in AD is associated with cognitive decline and hippocampal atrophy, supporting TREM2 as a putative 
peripheral biomarker for AD (38). 
Several pieces of evidence are in favour of a communication between the systemic immune 
system and the brain.  Experimental studies have demonstrated that systemic inflammation whether in 
the form of a chronic disease (e.g. osteoarthritis), or infection (e.g. LPS) can enhance AD pathology in 
animal models (22, 25, 26, 36).  This led to the prediction that systemic infection and inflammation 
could exaggerate the acute symptoms of disease, increase the ongoing tissue injury and impact on the 
rate of disease progression.  In clinical studies, the presence of systemic infection and inflammation, 
with raised peripheral pro-inflammatory cytokines, was associated with a marked increase in the rate 
of long-term cognitive decline and the neuropsychiatric features typical of sickness behaviour in AD 
patients (14, 15, 18).  This finding is consistent with information from in vivo PET imaging showing 
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that the cognitive decline is associated with the inflammatory signal in the brain (6).  The use of the 
tumour necrosis factor (TNF)-α inhibitor etanercept in a small randomized, placebo-controlled, 
double-blind study to block low-grade peripheral systemic inflammation in AD patients showed 
trends that favour etanercept compared to placebo (4).   
Further studies with additional antibodies to TREM2, as they are developed, will help clarify our 
understanding of this protein which genetics indicates is important in AD pathogenesis.  Overall, our 
demonstration here that despite TREM2 gene variation influencing risk of AD, TREM2 positive cells 
are largely restricted to the blood circulation, promotes a role for systemic inflammation in the 
development and progression of AD, and highlights the need for a greater understanding of the 
communication involved between the periphery and the brain. 
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Table 1: Characteristics of the cohort according to dementia status  
 
 
 
No dementia 
(n= 130) 
Dementia non-
AD pathology 
(n=65) 
Dementia with 
AD pathology 
(n=83) 
Unknown 
dementia 
status 
(n=21) 
Number of women† 66 (51) 49 (75) 53 (64) 10 (48) 
Age at death (years) †† 84 (77; 90) 89 (85; 93) 89 (83; 93) 86 (84; 91) 
Years since last cognitive 
assessment†† 
1·1 (0·5; 1·8) 1·7 (0·8; 3·0) 1·5 (0·8; 3·2) 2·5 (2·0; 3·4) 
MMSE at last assessment †† 25 (22; 28) 18 (11; 23) 11 (6; 17) 25 (22; 27) 
 
† n(%) 
†† median (interquartile range) 
AD: Alzheimer’s disease; MMSE: Mini-Mental State Examination  
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Table 2: Morphological characterisation of lesion age {Ellison, 2013 #4047;Hossmann, 2014 #3993;Kalaria, 2015 #4028} 
 
Very acute infarct <24hours 
Neuronal ischaemia, very early neuropil fragmentation, no macrophages, no neutrophils, no 
microvascular proliferation, no astrocytosis 
Acute infarct 1-3 days 
Neuronal ischaemia, early neuropil degeneration, no macrophages, +/-neutrophils, no 
microvascular proliferation, no astrocytosis 
Subacute infarct approx. 1 week 
Neuronal ischaemia, neuropil degeneration, foamy macrophages, no neutrophils, microvascular 
proliferation, surrounding early astrocytosis 
Old infarct several weeks to months/years 
Neuronal loss, advanced neuropil degeneration (cavitated), +/-foamy macrophages, no 
neutrophils, no microvascular proliferation, surrounding astrocytosis 
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Table 3: Expression of TREM2 and CD68 in cerebral infarcts of different ages 
 
 
ID 
 
Infarct age 
 
Morphological description 
 
CD68 
 
TREM2 
     
1 Very acute Very acute focal cortical ischaemia (<24hrs) - - 
2 Very acute Very acute focal cortical ischaemia (<24hrs) - - 
3 Acute Acute cortical infarct (1-3 days) - +++ 
4 Acute  
Multiple acute cortical/white matter septic microemboli +/- acute 
infarction (1-3 days) 
+/- +++ 
5 Acute 
Acute lesions [Multiple cortical/white matter septic microemboli + 
acute (1-3 days) and subacute (i.e. at least several days) infarcts] 
+/- ++ 
6 Acute Acute cortical infarct (1-3 days) - + 
7 Acute Acute cortical infarct (1-3 days) - + 
8 Acute Acute cortical infarct (1-3 days) - - 
9 Subacute Subacute cortical infarct (about 1 week) ++ +++ 
5 Subacute 
Subacute lesions [Multiple cortical/white matter septic microemboli + 
acute (1-3 days) and subacute (i.e. at least several days)] 
++ - 
10 Old Old cortical micro-infarct (>several months) + - 
11 Old Old infarct (a few weeks) +++ - 
12 Old Old cortical infarct (many months-years) + - 
13 Old Old cortical infarct (many months-years) + - 
14 Old Old white matter infarct (several months) ++ - 
15 Old Old cortical micro-infarct ++ - 
16 n/a No lesion - - 
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Figure 1: TREM2 immunostaining in spleen with (A) the anti-TREM2 antibody HPA010917 from Sigma and 
with (B) the anti-TREM2 AF1828 from R&D.  Haematoxylin counterstaining, scale bar = 50µm.  
 
88x36mm (300 x 300 DPI)  
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Figure 2: Iba1 and TREM2 immunolabelling.  (A) Iba1 staining recognises ramified microglia and 
perivascular macrophages; whereas (B) TREM2 staining in the same area detects only intravascular 
monocytes (*) but not microglia or perivascular macrophages (uninfarcted area).  Acute infarct showing (C) 
high expression Iba1 in microglia and perivascular macrophages and (D) TREM2-positive parenchymal cells 
within the infarct.  The surrounding un-infarcted area contains Iba1-positive (C) TREM2-negative microglia 
(D)(*).  The extravascular TREM2-positive cells in the infarcted parenchyma have similar morphology to the 
TREM2-positive intravascular monocytes and likely represent recruitment of circulating monocytes to the 
infarcted tissue. Haematoxylin counterstaining, scale bar (A-B) = 50µm, (C-D) = 100µm.  
 
110x84mm (300 x 300 DPI)  
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Figure 3: TREM2 and CD68 immunostaining in infarcts at different stages of evolution.  (A-C) Uninfarcted 
region.  (A) H&E staining showing preserved tissue.  (B) TREM2 immunohistochemistry labelling of 
monocytes within the lumen of a blood vessel, but not microglia in the surrounding brain parenchyma.  (C) 
CD68 immunohistochemistry showing staining of perivascular macrophages.  (D-F) Acute cortical infarct 
with early neuropil disruption, neuronal ischaemia and infiltration by neutrophils as observed on (D) H&E 
staining.  (E) TREM2 immunohistochemistry showing numerous TREM2 labelled cells infiltrating the acutely 
infarcted cortex and present within vascular lumens. The cells have the morphology of monocytes rather 
than foamy macrophages or process-bearing microglia.  (F) CD68 immunohistochemistry showing no 
significant labelling of cells indicating the infarct is so acute that no phagocytosis of cell debris by 
macrophage/microglia has begun.  (G) H&E staining showing an old cortical infarct with extensive neuropil 
disintegration and abundant foamy macrophages.  (H) TREM2 immunohistochemistry showing the foamy 
macrophages are not labelled.  A single monocyte is labelled within the lumen of a capillary within the 
infarct (inset top right).  (I) CD68 immunohistochemistry showing immunoreactivity of abundant foamy 
macrophages.  Counterstaining with Haematoxylin and eosin (H&E) for (A, D, G) and with Haematoxylin for 
(B, C, E, F, H, I); scale bar = 50µm.  
 
129x99mm (300 x 300 DPI)  
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